Last updated: 18 June 2019 at 5:18am EST

Peter Powchik Net Worth




The estimated Net Worth of Peter Powchik is at least $24.8 Миллион dollars as of 16 December 2015. Peter Powchik owns over 1,921 units of Regeneron Pharmaceuticals stock worth over $20,251,606 and over the last 18 years Peter sold REGN stock worth over $4,567,089.

Peter Powchik REGN stock SEC Form 4 insiders trading

Peter has made over 18 trades of the Regeneron Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently Peter exercised 1,921 units of REGN stock worth $99,950 on 16 December 2015.

The largest trade Peter's ever made was exercising 109,866 units of Regeneron Pharmaceuticals stock on 21 February 2012 worth over $1,988,575. On average, Peter trades about 16,684 units every 57 days since 2006. As of 16 December 2015 Peter still owns at least 17,742 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Peter Powchik stock trades at the bottom of the page.



Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis и Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.



What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.



Complete history of Peter Powchik stock trades at Regeneron Pharmaceuticals

инсайдер
Транзакция
Транзакция
Общая стоимость
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $99,950
16 Dec 2015
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $7,082,156
13 Aug 2015
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $1,300,750
31 Dec 2014
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $99,976
19 Dec 2014
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $1,470,240
31 Dec 2013
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $99,981
24 Dec 2013
Peter Powchik
SVP Clinical Development и Reg
Продажа $2,467,828
18 Dec 2013
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $3,281,163
13 Dec 2013
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $99,970
9 Jan 2013
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $637,500
2 Jan 2013
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $1,209,019
18 Dec 2012
Peter Powchik
SVP Clinical Development и Reg
Продажа $2,099,261
8 Nov 2012
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $252,000
18 Sep 2012
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $263,075
1 Aug 2012
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $252,000
25 Jul 2012
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $1,988,575
21 Feb 2012
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $236,852
1 Aug 2011
Peter Powchik
SVP Clinical Development и Reg
Реализация опциона $391,000
25 Jul 2011


Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: